S68 Epigenetics in Diabetes: From Diagnosis to Complications

Program: Symposia
Clinical/Translational Session
Monday, April 4, 2016: 11:45 AM-1:15 PM
BR East (BCEC)
Chair:
Evan D Rosen, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA

Nothing to Disclose: EDR
11:45 AM
Charlotte Ling, PhD, Epigenetics and Diabetes, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Clinical Research Centre, Malmö, Sweden
Nothing to Disclose: CL
12:15 PM
Sona Kang, PhD, Medicine, University of California-Berkeley, Berkeley, CA
Nothing to Disclose: SK
12:30 PM
Linus Tzu-Yen Tsai, MD, PhD, Division Of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconness Medical Center, Boston, MA
Disclosure Not Provided: LTYT
12:45 PM
Rama Natarajan, PhD, Department of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA
Nothing to Disclose: RN
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire